Literature DB >> 33127622

Cyclotron-Produced 132La as a PET Imaging Surrogate for Therapeutic 225Ac.

Eduardo Aluicio-Sarduy1, Todd E Barnhart1, Jamey Weichert2, Reinier Hernandez1,2, Jonathan W Engle3,2.   

Abstract

The aim of this work was to explore 132La as a PET imaging surrogate for 225Ac using a DOTA-based, tumor-targeting alkylphosphocholine (NM600).
Methods: 132La was produced on a biomedical cyclotron. For in vivo experiments, mice bearing 4T1 tumors were administered 132La-NM600, and PET/CT scans were acquired up to 24 h after injection. After the last time point, the ex vivo tissue distribution was measured to corroborate the in vivo PET data. The ex vivo tissue distribution in mice was determined at 4 and 24 h after injection of 225Ac-NM600.
Results: PET/CT images showed elevated, persistent 132La-NM600 uptake in the tumor. Low bone accumulation confirmed the in vivo stability of the conjugate. Ex vivo biodistribution studies validated the image-derived quantitative data, and the comparison of the 132La-NM600 and 225Ac-NM600 tissue distributions revealed a similar biodistribution for the 2 radiotracers.
Conclusion: These findings suggest that 132La is a suitable imaging surrogate to probe the in vivo biodistribution of 225Ac radiotherapeutics.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET; actinium; radiolanthanum; theranostics; α-emitters

Mesh:

Year:  2020        PMID: 33127622      PMCID: PMC8882879          DOI: 10.2967/jnumed.120.255794

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY.

Authors:  Mike Sathekge; Frank Bruchertseifer; Mariza Vorster; Ismaheel Lawal; Otto Knoesen; Johncy Mahapane; Cindy Davis; Florette Reyneke; Alex Maes; Clemens Kratochwil; Thabo Lengana; Frederik Giesel; Christophe Van de Wiele; Alfred Morgenstern
Journal:  J Nucl Med       Date:  2019-05-17       Impact factor: 10.057

2.  Development of an in vitro model for assessing the in vivo stability of lanthanide chelates.

Authors:  W P Li; D S Ma; C Higginbotham; T Hoffman; A R Ketring; C S Cutler; S S Jurisson
Journal:  Nucl Med Biol       Date:  2001-02       Impact factor: 2.408

3.  Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications.

Authors:  Eduardo Aluicio-Sarduy; Nikki A Thiele; Kirsten E Martin; Brett A Vaughn; Justin Devaraj; Aeli P Olson; Todd E Barnhart; Justin J Wilson; Eszter Boros; Jonathan W Engle
Journal:  Chemistry       Date:  2020-01-09       Impact factor: 5.236

4.  Utilizing High-Energy γ-Photons for High-Resolution 213Bi SPECT in Mice.

Authors:  Jan de Swart; Ho Sze Chan; Marlies C Goorden; Alfred Morgenstern; Frank Bruchertseifer; Freek J Beekman; Marion de Jong; Mark W Konijnenberg
Journal:  J Nucl Med       Date:  2015-12-03       Impact factor: 10.057

5.  An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy.

Authors:  Nikki A Thiele; Victoria Brown; James M Kelly; Alejandro Amor-Coarasa; Una Jermilova; Samantha N MacMillan; Anastasia Nikolopoulou; Shashikanth Ponnala; Caterina F Ramogida; Andrew K H Robertson; Cristina Rodríguez-Rodríguez; Paul Schaffer; Clarence Williams; John W Babich; Valery Radchenko; Justin J Wilson
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-16       Impact factor: 15.336

Review 6.  An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.

Authors:  Alfred Morgenstern; Christos Apostolidis; Clemens Kratochwil; Mike Sathekge; Leszek Krolicki; Frank Bruchertseifer
Journal:  Curr Radiopharm       Date:  2018

7.  90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Authors:  Reinier Hernandez; Kirsti L Walker; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Ravi Patel; Christopher D Zahm; Anatoly N Pinchuk; Christopher F Massey; Ariana N Bitton; Ryan J Brown; Paul M Sondel; Zachary S Morris; Jonathan W Engle; Christian M Capitini; Jamey P Weichert
Journal:  Commun Biol       Date:  2019-02-26

8.  Production and in vivo PET/CT imaging of the theranostic pair 132/135La.

Authors:  Eduardo Aluicio-Sarduy; Reinier Hernandez; Aeli P Olson; Todd E Barnhart; Weibo Cai; Paul A Ellison; Jonathan W Engle
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

9.  Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer.

Authors:  Vanessa J Kelly; Shu-Ta Wu; Vijay Gottumukkala; Richard Coelho; Keryn Palmer; Surabhi Nair; Timothy Erick; Rahul Puri; Ohad Ilovich; Pinku Mukherjee
Journal:  Theranostics       Date:  2020-05-25       Impact factor: 11.556

10.  177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer.

Authors:  Reinier Hernandez; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Christopher F Massey; Anatoly N Pinchuk; Ariana N Bitton; Ravi Patel; Ray Zhang; Aakarsha V Rao; Gopal Iyer; Jonathan W Engle; Jamey P Weichert
Journal:  J Nucl Med       Date:  2019-12-20       Impact factor: 10.057

View more
  5 in total

Review 1.  Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.

Authors:  George Sgouros; Eric Frey; Yong Du; Rob Hobbs; Wesley Bolch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-16       Impact factor: 9.236

Review 2.  Cutting edge rare earth radiometals: prospects for cancer theranostics.

Authors:  Alexander W E Sadler; Leena Hogan; Benjamin Fraser; Louis M Rendina
Journal:  EJNMMI Radiopharm Chem       Date:  2022-08-26

Review 3.  Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.

Authors:  K J H George; S Borjian; M C Cross; J W Hicks; P Schaffer; M S Kovacs
Journal:  RSC Adv       Date:  2021-09-21       Impact factor: 4.036

4.  Advancing Chelation Strategies for Large Metal Ions for Nuclear Medicine Applications.

Authors:  Aohan Hu; Justin J Wilson
Journal:  Acc Chem Res       Date:  2022-03-01       Impact factor: 24.466

5.  First In Vivo and Phantom Imaging of Cyclotron-Produced 133La as a Theranostic Radionuclide for 225Ac and 135La.

Authors:  Bryce J B Nelson; Simon Ferguson; Melinda Wuest; John Wilson; M John M Duke; Susan Richter; Hans Soenke-Jans; Jan D Andersson; Freimut Juengling; Frank Wuest
Journal:  J Nucl Med       Date:  2021-08-12       Impact factor: 10.057

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.